Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells 5,251 Shares of Stock

Key Points

• COO Jeremy Chadwick sold 5,251 shares on April 14 at an average price of $90 for proceeds of $472,590, reducing his stake by 7.9% to 61,202 shares.
• Shares traded down to $86.14 (down $2.86) after the quarter in which Kymera missed EPS at ($0.97) vs. ($0.77) expected and reported revenue of $2.87 million, a Sharp decline from estimates and year-ago levels.
• Despite mixed operational results, large institutions like Baker Bros., Avoro, T. Rowe and Vanguard have increased stakes, and analysts mostly rate KYMR a Buy with an average target of about $118.90.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy Chadwick sold 5,251 shares of Kymera Therapeutics stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $90.00, for a total transaction of $472,590.00. Following the transaction, the chief operating officer directly owned 61,202 shares of the company's stock, valued at approximately $5,508,180. This trade represents a 7.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Kymera Therapeutics Trading Down 3.2%

Shares of NASDAQ:KYMR traded down $2.86 on Thursday, hitting $86.14. The company had a trading volume of 554,950 shares, compared to its average volume of 732,626. The stock has a market cap of $7.03 billion, a price-to-earnings ratio of -23.41 and a beta of 2.28. The stock has a 50 day moving average price of $83.69 and a 200 day moving average price of $74.15. Kymera Therapeutics, Inc. has a 1-year low of $24.72 and a 1-year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The company had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. During the same quarter in the prior year, the business posted ($0.88) EPS. The business's quarterly revenue was down 60.8% compared to the same quarter last year. Sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Institutional Trading of Kymera Therapeutics

Several hedge funds have recently modified their holdings of the stock. Baker BROS. Advisors LP increased its stake in Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company's stock valued at $673,620,000 after purchasing an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC increased its position in Kymera Therapeutics by 17.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company's stock valued at $581,610,000 after buying an additional 1,124,747 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company's stock worth $479,258,000 after buying an additional 1,061,957 shares during the period. Vanguard Group Inc. boosted its holdings in Kymera Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company's stock worth $487,685,000 after acquiring an additional 845,922 shares in the last quarter. Finally, Holocene Advisors LP bought a new position in Kymera Therapeutics in the third quarter worth approximately $47,563,000.

Analyst Ratings Changes

A number of brokerages recently issued reports on KYMR. Stephens lifted their price objective on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the company an "overweight" rating in a research note on Monday, March 2nd. Morgan Stanley reaffirmed an "overweight" rating and issued a $123.00 target price on shares of Kymera Therapeutics in a report on Thursday, February 26th. Jefferies Financial Group started coverage on Kymera Therapeutics in a research note on Monday, March 16th. They issued a "buy" rating and a $110.00 price target on the stock. Citigroup upped their price objective on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $108.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Kymera Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $118.90.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.